 |
|
COMMENTS AND OPINIONS
Allergic Contact Dermatitis: Another Adverse Effect of Over-the-counter Topical Hydrocortisone—Reply
William H. Eaglstein, MD;
Scott M. Ravis
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We thank Watsky and Warshaw for their interest and insightful comments. As they point out, ACD was not listed as an adverse effect of treatment with topical hydrocortisone in our commentary.1 We did not mention the potential adverse effect of ACD to topical hydrocortisone because it did not play a role in the debate regarding the appropriateness of permitting OTC sale of topical hydrocortisone preparations.
As pointed out by Watsky and Warshaw, the ready availability of OTC hydrocortisone products (especially in structural class A) likely contributes to a high prevalence of clinically significant positive patch test results to corticosteroid markers in selected patch-tested populations. How this translates to the prevalence of corticosteroid-induced ACD in the population at large is apparently not known. At what level corticosteroid-induced ACD might be a public health concern requiring consideration of removing products from the market . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED LETTER
Allergic Contact Dermatitis: Another Adverse Effect of Over-the-counter Topical Hydrocortisone
Kalman L. Watsky and Erin M. Warshaw
Arch Dermatol. 2007;143(9):1217.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Topical Hydrocortisone From Prescription to Over-the-Counter Sale: A Past Controversy: A Cautionary Tale
Scott Michael Ravis and William H. Eaglstein
Arch Dermatol. 2007;143(3):413-415.
EXTRACT
| FULL TEXT
|
